Skip to main content
. 2021 Jan 28;31(4):e12918. doi: 10.1111/bpa.12918

FIGURE 11.

FIGURE 11

Clinical outcomes for patients with intracranial mesenchymal tumors with FET‐CREB fusion from this study combined with all previously reported cases in the literature (see Table 4). A, Kaplan–Meier plot of overall survival demonstrates a median overall survival >60 months. B, Kaplan–Meier plot of progression‐free survival demonstrates that a majority of patients experience disease recurrence with a median interval of 28 months. C, Kaplan–Meier plot of overall survival stratified by fusion type. While no statistically significant difference in overall survival based on fusion type is observed, three patients with tumors containing EWSR1‐ATF1 fusion succumbed to disease, while all patients with EWSR1‐CREB1 or EWSR1‐CREM fusion remained alive at time of last clinical follow‐up. D, Kaplan–Meier plot of progression‐free survival stratified by fusion type. No significant difference was observed based on fusion type (median recurrence‐free survival: EWSR1‐ATF1, 16 months; EWRS1‐CREB1, 49 months; EWSR1‐CREM, 28 months)